Lipid-Raft-Targeted Molecular Self-Assembly Inactivates YAP to Treat Ovarian Cancer

Nano Lett. 2021 Jan 13;21(1):747-755. doi: 10.1021/acs.nanolett.0c04435. Epub 2020 Dec 23.

Abstract

The Yes-associated protein (YAP) is a major oncoprotein responsible for cell proliferation control. YAP's oncogenic activity is regulated by both the Hippo kinase cascade and uniquely by a mechanical-force-induced actin remodeling process. Inspired by reports that ovarian cancer cells specifically accumulate the phosphatase protein ALPP on lipid rafts that physically link to actin cytoskeleton, we developed a molecular self-assembly (MSA) technology that selectively halts cancer cell proliferation by inactivating YAP. We designed a ruthenium-complex-peptide precursor molecule that, upon cleavage of phosphate groups, undergoes self-assembly to form nanostructures specifically on lipid rafts of ovarian cancer cells. The MSAs exert potent, cancer-cell-specific antiproliferative effects in multiple cancer cell lines and in mouse xenograft tumor models. Our work illustrates how basic biochemical insights can be exploited as the basis for a nanobiointerface fabrication technology which links nanoscale protein activities at specific subcellular locations to molecular biological activities to suppress cancer cell proliferation.

Keywords: Hippo signaling; actin-remodeling; lipid raft; molecular self-assembly; ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins
  • Animals
  • Female
  • Humans
  • Membrane Microdomains
  • Mice
  • Ovarian Neoplasms* / drug therapy
  • Protein Serine-Threonine Kinases* / metabolism
  • Signal Transduction

Substances

  • Actins
  • Protein Serine-Threonine Kinases